Clinical trial
Arimidex in McCune Albright Syndrome
NCT00055302 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00055302 |
|---|---|
| Title | Arimidex in McCune Albright Syndrome |
| Official title | An Open-label Study Evaluating the Safety and Efficacy of Anastrozole™ (ARIMIDEX) in the Treatment of Precocious Puberty in Girls With McCune-Albright Syndrome |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | McCune-Albright Syndrome |
| Intervention type | Drug |
| Interventions | Arimidex 1 mg |
| Enrollment | 40 |
| Start date | Aug 1, 2002 |
| Primary completion | Feb 1, 2006 |
| Completion | Aug 1, 2015 |
| First posted | Feb 26, 2003 |
| Last update posted | Sep 1, 2015 |
| Countries | France, Germany, Italy, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: